KRYS — Krystal Biotech, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711279 ·
Last close
$298.55
Market Cap
$8.85B
52W High
$382.54
52W Low
$202.99
ADV30
291,674
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 127,341,000 | 119,785,000 | 71,145,000 | 63,068,000 | 1,586,056,000 | 462,841,000 | 150,472,000 |
| Jun 2026 | 119,222,000 | 112,785,000 | 58,417,000 | 54,768,000 | 1,500,648,000 | 427,740,000 | 141,522,000 |
| Mar 2026 | 116,357,000 | 110,034,000 | 53,689,000 | 55,932,000 | 1,396,967,000 | 501,313,000 | 120,238,000 |
| Dec 2025 | 107,105,000 | 100,513,000 | 44,270,000 | 51,400,000 | 1,333,794,000 | 496,304,000 | 114,234,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$323,928,000
Investing CF
$-271,988,000
Financing CF
$23,673,000
CapEx
$-13,848,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$7.37
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$197,931,000
Inventory
$50,787,000
Receivables
$133,115,000
ST Investments
$449,010,000
EBIT TTM
$227,521,000
Pretax Income TTM
$258,797,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$470,024,992
EBITDA
$229,034,000
Free Cash Flow
$221,590,880
Enterprise Value
$8,012,855,808
Total Cash
$911,851,008
Total Debt
$8,588,000
Shares Out
29,633,472
Trailing EPS
$7.36
Book Value
$48.45
ROE
17.5%
ROA
10.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 389,130,000 | 161,295,000 | 204,831,000 | 1,333,794,000 | 114,234,000 | 1,219,560,000 | 200,865,000 |
| Dec 2024 | 290,515,000 | 103,248,000 | 89,159,000 | 1,055,838,000 | 109,458,000 | 946,380,000 | 123,420,000 |
| Dec 2023 | 50,699,000 | -97,117,000 | 10,932,000 | 818,355,000 | 39,714,000 | 778,641,000 | -88,804,000 |
| Dec 2022 | 0 | -120,196,000 | -139,975,000 | 558,450,000 | 36,219,000 | 522,231,000 | -100,569,000 |
TTM Snapshot
Revenues TTM
$440,484,000
NetIncome TTM
$241,465,000
OpCashFlow TTM
—
Assets (Latest)
$1,500,648,000
Forward EPS
$9.23
Max Pain — expiry 2027-06-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $290.00 · spot: $315.34 · call volume: 358 · put volume: 346
Expected Move to 2027-06-17:
±$68.03
(21.57%) —
implied range
$247.31 –
$383.37
· ATM straddle on $320.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCVX | Vaxcyte, Inc. | $9.40B | $59.40 | — |
| QGEN | QIAGEN N.V. | $10.27B | $49.75 | — |
| RGEN | REPLIGEN CORP | $10.30B | $162.18 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.37B | $121.52 | — |
| TWST | Twist Bioscience Corp | $7.43B | $112.00 | — |
News headlines (Yahoo Finance, 1h cache)
Krystal Biotech to Present at Upcoming Investor Conferences
2026-11-10 13:00 · Yahoo
Krystal Biotech (KRYS) Stock Stays Above Fair Value After Buyback Plan
2026-11-03 06:11 · Yahoo
Earnings Beat May Change The Case For Krystal Biotech (KRYS) Stock
2026-11-03 05:10 · Yahoo
Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?
2026-11-03 02:16 · Yahoo
Krystal Biotech Sinks 11% Despite Q3 Beat as Eye Trial Enrollment “Progressed Slower Than Initially Anticipated”
2026-11-03 00:51 · Yahoo
Krystal Biotech Inc (KRYS) (Q3 2026) Earnings Call Highlights: Vyjuvek Revenue Jumps 30% to ...
2026-11-02 23:03 · Yahoo
Krystal Biotech, Inc. Q3 2026 Earnings Call Summary
2026-11-02 17:57 · Yahoo
Krystal Biotech (KRYS) Q3 2026 Earnings Call Transcript
2026-11-02 16:58 · Yahoo
Krystal Biotech Q3 Earnings Call Highlights
2026-11-02 16:14 · Yahoo
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates
2026-11-02 15:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.